or Try an Advanced Search...

    Renal Cell Carcinoma Stocks List

    Symbol Grade Name % Change
    ACHL C Achilles Therapeutics plc 0.00
    BCAB F BioAtla, Inc. -6.08
    AIM F AIM ImmunoTech Inc. 5.85
    AGEN F Agenus Inc. 7.12
    TCON F TRACON Pharmaceuticals, Inc. -31.40
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Cancer Medicine Melanoma Carcinoma Clinical Medicine Biopharmaceutical Bladder Cancer Cancer Immunotherapy Drugs Health Care Hepatocellular Carcinoma Infectious Diseases Non Small Cell Lung Cancer Small Cell Lung Cancer Targeted Therapy Acid Advanced Non Small Cell Lung Cancer Age Related Macular Degeneration Alzheimer's Disease Antineoplastic Drugs

    Related ETFs - A few ETFs which own one or more of the above listed Renal Cell Carcinoma stocks.

    Symbol Grade Name Weight
    FORH C Formidable ETF 0.79
    IWC B iShares Microcap ETF 0.03
    DFAS B Dimensional U.S. Small Cap ETF 0.0
    IWM B iShares Russell 2000 ETF 0.0
    ITOT A iShares Core S&P Total U.S. Stock Market ETF 0.0
    View all Renal Cell Carcinoma ETFs...
    Compare ETFs
    Compare DFAS to ITOT Compare FORH to IWC Compare IWM to ITOT

        Renal Cell Carcinoma Stocks Recent News

        Date Stock Title
        Nov 19 ACHL US Penny Stocks To Watch In November 2024
        Nov 19 AGEN Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
        Nov 19 AIM AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer
        Nov 19 ACHL Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
        Nov 19 AIM Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board
        Nov 18 AGEN Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
        Nov 16 AIM AIM ImmunoTech Inc (AIM) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
        Nov 15 AIM AIM ImmunoTech Inc. (AIM) Q3 2024 Earnings Call Transcript
        Nov 15 AGEN Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround
        Nov 15 AIM AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
        Nov 15 AIM AIM ImmunoTech GAAP EPS of -$0.06
        Nov 15 AIM Earnings Scheduled For November 15, 2024
        Related Industries: Biotechnology
        Related Stock Lists: Cancer Medicine Melanoma Carcinoma Clinical Medicine Biopharmaceutical Bladder Cancer Cancer Immunotherapy Drugs Health Care Hepatocellular Carcinoma Infectious Diseases Non Small Cell Lung Cancer Small Cell Lung Cancer Targeted Therapy Acid Advanced Non Small Cell Lung Cancer Age Related Macular Degeneration Alzheimer's Disease Antineoplastic Drugs
        Renal Cell Carcinoma

        Renal cell carcinoma (RCC) is a type of cancer that starts in the cells of the kidney. It is the most common type of kidney cancer in adults. RCC is usually found in one kidney, but it can occur in both kidneys at the same time. Symptoms of RCC can include blood in the urine, a lump in the abdomen, and pain in the side or back. Treatment for RCC may include surgery, radiation therapy, chemotherapy, or targeted therapy.

        Browse All Tags